{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:18:56Z","timestamp":1761895136278},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.critrevonc.2010.07.003","type":"journal-article","created":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T09:10:08Z","timestamp":1280999408000},"page":"135-143","source":"Crossref","is-referenced-by-count":11,"title":["The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era"],"prefix":"10.1016","volume":"79","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2010.07.003_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukaemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukaemia-advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene","volume":"40","author":"Sattler","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib4","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukaemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib5","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?","volume":"115","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib8","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib9","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/beha.2001.0190","article-title":"Minimal residual disease in chronic myeloid leukaemia patients","volume":"15","author":"Hochhaus","year":"2002","journal-title":"Best Pract Clin Haematol"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib11","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.leu.2401811","article-title":"Detection and quantification of residual disease in chronic myelogenous leukemia","volume":"14","author":"Hochhaus","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib12","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood.V95.8.2659","volume":"95","author":"Serrano","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib13","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood.V99.10.3861","article-title":"Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation","volume":"99","author":"Olavarria","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib15","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib16","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib17","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"M\u00fcller","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib19","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib20","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib21","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2007-08-103499","article-title":"Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party","volume":"113","author":"Castagnetti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib22","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1200\/JCO.2008.20.3869","article-title":"High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses","volume":"27","author":"Cortes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V112.11.183.183","article-title":"Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (CP): first results of the phase III (SPIRIT) trial from the French CML Group (FI LMC)","volume":"112","author":"Guilhot","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib24","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib26","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3324\/haematol.12265","article-title":"Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib27","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","article-title":"Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha","volume":"16","author":"Merx","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib28","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/annonc\/mdj106","article-title":"Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients","volume":"17","author":"Martinelli","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib30","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib31","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","article-title":"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML","volume":"107","author":"Press","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib32","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V112.11.333.333","article-title":"Molecular response to first line imatinib therapy is predictive for long term event free survival in patients with chronic phase chronic myelogenous leukemia\u2014an interim analysis of the randomized German CML Study IV","volume":"112","author":"Muller","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib34","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib35","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib36","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1158\/1078-0432.CCR-05-2574","article-title":"Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients","volume":"12","author":"Iacobucci","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib37","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib38","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-08-1195","article-title":"Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response","volume":"15","author":"Palandri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib39","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2008.18.6999","article-title":"Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2009.07646.x","article-title":"Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?","volume":"145","author":"Marin","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib42","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood.V112.11.1102.1102","article-title":"The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any relapses occur early","volume":"112","author":"Ross","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib43","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood.V114.22.859.859","article-title":"Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients","volume":"114","author":"Mahon","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib44","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib45","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib46","doi-asserted-by":"crossref","first-page":"984","DOI":"10.6004\/jnccn.2009.0065","article-title":"NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia","volume":"7","author":"O\u2019Brien","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.critrevonc.2010.07.003_bib47","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842810001708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842810001708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T01:45:50Z","timestamp":1591753550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842810001708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S1040842810001708"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2010.07.003","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}